Edgar Filing: Costantino John R

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â Costantino John R

2. Date of Event Requiring Statement (Month/Day/Year)
12/19/2006

3. Issuer Name and Ticker or Trading Symbol
ARTES MEDICAL INC [ARTE]

(Last)

(First)

(Middle)

5870 PACIFIC CENTER BOULEVARD

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

SAN DIEGO,Â CAÂ 92121

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series E Convertible Preferred Stock	Â ⁽¹⁾	Â ⁽¹⁾	Common Stock	197,458 ⁽²⁾	$ ⁽¹⁾	I	By NGN Biomed Opportunity I GmbH & Co. Beteiligungs KG ⁽³⁾
Warrant (Right to Purchase Series E Preferred Stock)	02/14/2006	02/14/2011	Common Stock ⁽⁴⁾	59,237 ⁽²⁾	$ 10.63	I	By NGN Biomed Opportunity I GmbH & Co. Beteiligungs KG ⁽³⁾
Series E Convertible Preferred Stock	Â ⁽¹⁾	Â ⁽¹⁾	Common Stock	273,129 ⁽²⁾	$ ⁽¹⁾	I	By NGN Biomed Opportunity I, L.P. ⁽³⁾
Warrant (Right to Purchase Series E Preferred Stock)	02/14/2006	02/14/2011	Common Stock ⁽⁴⁾	81,938 ⁽²⁾	$ 10.63	I	By NGN Biomed Opportunity I, L.P. ⁽³⁾
Stock Option (Right to Buy)	Â ⁽⁵⁾	11/22/2016	Common Stock	31,796	$ 10.63	I	By NGN Capital LLC ⁽³⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Costantino John R 5870 PACIFIC CENTER BOULEVARD SAN DIEGO,Â CAÂ 92121	Â X	Â	Â	Â

Signatures

/s/ John R. Costantino		12/19/2006
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Immediately following the closing of the initial public offering of the Issuer?s Common Stock all outstanding shares of Preferred Stock will be automatically converted, for no additional consideration, into shares of the Issuer's Common Stock.
(2)	Reflects a 1 for 4.25 reverse stock split, effected prior to the effectiveness of the registration statement filed in connection with the Issuer?s initial public offering, pursuant to which each share of Series E Convertible Preferred Stock will become convertible into approximately 0.235 of a share of common stock.
(3)	Mr. Costantino is the Managing General Partner of NGN Capital LLC. NGN Capital LLC is the managing limited partner of NGN BioMed Opportunity I, GmbH & Co. Beteiligungs KG and the sole general partner of NGN BioMed I, GP, L.P, the sole general partner of NGN BioMed Opportunity I, L.P. Mr. Costantino disclaims beneficial ownership of the securities held directly by NGN BioMed Opportunity I, GmbH & Co. Beteiligungs KG, NGN BioMed Opportunity I, L.P. and NGN Capital LLC except to the extent of any indirect pecuniary interest in his distributive share therein.
(4)	This Warrant was originally exercisable for shares of the Issuer's Series E Convertible Preferred Stock. In connection with the closing of the initial public offering of the Issuer?s Common Stock all shares of Series E Convertible Preferred Stock underlying this Warrant will be automatically converted, for no additional consideration, into shares of the Issuer's Common Stock.
(5)	This option vests and becomes exercisable in 48 equal installments on each monthly anniversary of June 9, 2006.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.